The global structural heart devices market was valued at USD 13.44 billion in 2022 and is projected to reach USD 31.71 billion by 2030, growing at a CAGR of 11.33% during the forecast period. Driven by the rising prevalence of congenital and acquired structural heart diseases, growing elderly population, and advancements in minimally invasive surgical techniques, the market is witnessing strong growth. North America is expected to retain its dominant position owing to early technology adoption, robust healthcare infrastructure, and favorable reimbursement policies. Structural heart devices are medical devices used to treat structural abnormalities of the heart, including defects in valves, chambers, walls, and vessels. These devices assist in restoring normal heart function and improving patient outcomes in both congenital and acquired heart conditions.
Historical Growth and Evolution
Historically, structural heart disorders were primarily treated via open-heart surgeries. Over the past two decades, technological innovations have enabled the development of transcatheter-based interventions, such as TAVR (Transcatheter Aortic Valve Replacement), which have revolutionized the treatment landscape by significantly reducing recovery time and procedural risks. Regulatory approvals and R&D investments have accelerated the availability of advanced devices globally.
Major Categories
-
Heart Valve Repair and Replacement Devices
-
Annuloplasty Rings
-
Occluders and Closure Devices
-
Left Atrial Appendage Closure (LAAC) Devices
-
Transcatheter Mitral and Aortic Valve Implants
Key Platforms
-
Transcatheter Procedures
-
Surgical Interventions
-
Hybrid Approaches
Market Dynamics
Drivers
-
Rising prevalence of congenital and acquired structural heart diseases
-
Increasing geriatric population and associated cardiac conditions
-
Demand for minimally invasive procedures with shorter recovery times
-
Technological advancements in imaging and device precision
-
Favorable government initiatives and reimbursement policies
Restraints
-
High cost of structural heart device procedures
-
Limited accessibility to advanced healthcare facilities in low-income regions
-
Stringent regulatory approval processes
-
Risk of complications, including device malfunction or need for reoperation
Opportunities
-
Emerging economies investing in healthcare infrastructure
-
Expansion of catheter-based procedures in developing regions
-
Integration of AI and robotic technologies in surgical applications
-
Growing awareness and screening programs for early diagnosis
Market Segmentation
By Type
-
Heart Valve Devices
-
Occluders and Closure Devices
-
Annuloplasty Rings
-
Accessories and Delivery Systems
-
Others
By Procedure
-
Transcatheter Aortic Valve Replacement (TAVR)
-
Transcatheter Mitral Valve Repair (TMVR)
-
Atrial Septal Defect (ASD) Closure
-
Ventricular Septal Defect (VSD) Closure
-
Left Atrial Appendage (LAA) Closure
-
Others
By End-User
-
Hospitals
-
Specialty Cardiac Centers
-
Ambulatory Surgical Centers
By Region
-
North America
-
Europe
-
Asia-Pacific
-
Latin America
-
Middle East & Africa
Competitive Landscape
The structural heart devices market is dominated by global medtech companies known for innovation, global reach, and extensive R&D investments.
Key Players Include:
-
Medtronic plc: Leading in TAVR systems and mitral valve therapies.
-
Edwards Lifesciences Corporation: Dominant in heart valve technologies, especially aortic and mitral valve devices.
-
Abbott Laboratories: Strong portfolio of occluders, closure devices, and valve repair solutions.
-
Boston Scientific Corporation: Offers LAA closure devices and other structural heart solutions.
-
LivaNova PLC: Known for surgical valve replacements and repair systems.
-
JenaValve Technology, Inc.: Specialized in transcatheter valve technologies.
-
Braile Biomédica: A growing player in emerging markets, especially in Latin America.
-
CryoLife, Inc.: Focused on surgical heart valve repair and biologic devices.
M&A activity, geographic expansion, and innovation in transcatheter and minimally invasive solutions are key strategic areas for these players.
Region-Wise Trends
North America remains the largest market due to high prevalence of structural heart disorders, robust reimbursement environment, and early adoption of advanced devices. The U.S. leads globally in TAVR and TMVR procedures.
Europe is witnessing significant growth supported by favorable clinical guidelines, increasing geriatric population, and strong healthcare infrastructure. Germany, France, and the UK are key contributors.
Asia-Pacific shows promising potential driven by growing healthcare awareness, improving medical infrastructure, and rising investments by global players. Countries like China, India, and Japan are expected to see rapid adoption of minimally invasive cardiac solutions.
Latin America is gradually expanding due to improvements in healthcare access and economic growth, though affordability and awareness remain challenges.
Middle East & Africa are in the early stages of market development, with government-led healthcare reforms and investments in cardiac care acting as key enablers.